Guobang Pharma Ltd Net Assets

Latest as of June 2026: CN¥8.40 Billion CNY ≈ $1.23 Billion USD

Guobang Pharma Ltd net assets. Based on the latest financial reports, Guobang Pharma Ltd (605507) has net assets worth CN¥8.40 Billion CNY (≈ $1.23 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.38 Billion ≈ $1.67 Billion USD) and total liabilities (CN¥2.98 Billion ≈ $436.31 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Guobang Pharma Ltd equity growth rate to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥8.40 Billion
% of Total Assets	73.81%
Annual Growth Rate	18.45%
5-Year Change	34.82%
10-Year Change	N/A
Growth Volatility	28.45

Net Assets of Guobang Pharma Ltd (2017–2025)

Net assets of Guobang Pharma Ltd from 2017 to 2025. This chart illustrates how Guobang Pharma Ltd's net assets have evolved over time, based on quarterly financial data. See 605507 equity to assets ratio to measure how much of total assets are equity-financed.

Annual Net Assets for Guobang Pharma Ltd (2017–2025)

The table below shows the annual net assets of Guobang Pharma Ltd from 2017 to 2025. For live market cap and overall valuation, see 605507 stock market capitalisation.

Year	Net Assets	Change
2025-12-31	CN¥8.56 Billion ≈ $1.25 Billion	+6.25%
2024-12-31	CN¥8.05 Billion ≈ $1.18 Billion	+8.27%
2023-12-31	CN¥7.44 Billion ≈ $1.09 Billion	+3.95%
2022-12-31	CN¥7.15 Billion ≈ $1.05 Billion	+12.75%
2021-12-31	CN¥6.35 Billion ≈ $928.57 Million	+93.81%
2020-12-31	CN¥3.27 Billion ≈ $479.11 Million	+25.17%
2019-12-31	CN¥2.62 Billion ≈ $382.78 Million	+0.92%
2018-12-31	CN¥2.59 Billion ≈ $379.31 Million	+17.43%
2017-12-31	CN¥2.21 Billion ≈ $323.00 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guobang Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 340.6% over the analyzed period, indicating profitable operations and earnings retention.

Guobang Pharma Ltd Net Assets Breakdown (December 2025)

Guobang Pharma Ltd net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Retained Earnings	CN¥4.13 Billion	48.23%
Other Components	CN¥4.43 Billion	51.77%
Total Equity	CN¥8.55 Billion	100.00%

Guobang Pharma Ltd Competitors by Market Cap

The table below lists competitors of Guobang Pharma Ltd ranked by their market capitalization.

Company	Market Cap
Greif Bros Corporation NYSE:GEF	$1.80 Billion
Dime Community Bancshares, Inc. NYSE:DCOM	$1.80 Billion
Baoding Heavy Industry Co Ltd SHE:002552	$1.80 Billion
Wuhan Yangtze Communication Industry Group Co Ltd SHG:600345	$1.80 Billion
A10 Network NYSE:ATEN	$1.80 Billion
Star Petroleum Refining Co Ltd BK:SPRC	$1.80 Billion
Sonos Inc NASDAQ:SONO	$1.80 Billion
Ruentex Industries Ltd TW:2915	$1.80 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guobang Pharma Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 8,047,340,282 to 8,553,123,737, a change of 505,783,455 (6.3%).
Net income of 820,820,433 contributed positively to equity growth.
Dividend payments of 359,627,313 reduced retained earnings.
Other comprehensive income decreased equity by 212,760,772.
Other factors increased equity by 257,351,107.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥820.82 Million	+9.6%
Dividends Paid	CN¥359.63 Million	-4.2%
Other Comprehensive Income	CN¥-212.76 Million	-2.49%
Other Changes	CN¥257.35 Million	+3.01%
Total Change	CN¥-	6.29%

Book Value vs Market Value Analysis

This analysis compares Guobang Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.44x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 6.94x to 1.44x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	CN¥2.26	CN¥15.71	x
2018-12-31	CN¥2.62	CN¥15.71	x
2019-12-31	CN¥4.68	CN¥15.71	x
2020-12-31	CN¥5.86	CN¥15.71	x
2021-12-31	CN¥11.36	CN¥15.71	x
2022-12-31	CN¥12.80	CN¥15.71	x
2023-12-31	CN¥13.35	CN¥15.71	x
2024-12-31	CN¥14.41	CN¥15.71	x
2025-12-31	CN¥10.93	CN¥15.71	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guobang Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.60%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 13.65%
• Asset Turnover: 0.55x
• Equity Multiplier: 1.28x
Recent ROE (9.60%) is below the historical average (13.52%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2017	16.46%	6.12%	0.72x	3.73x	CN¥69.78 Million
2018	16.90%	6.43%	0.75x	3.50x	CN¥86.07 Million
2019	12.04%	8.28%	0.80x	1.82x	CN¥53.27 Million
2020	24.73%	19.26%	0.76x	1.68x	CN¥482.53 Million
2021	11.13%	15.67%	0.60x	1.18x	CN¥71.42 Million
2022	12.87%	16.10%	0.63x	1.26x	CN¥205.38 Million
2023	8.24%	11.45%	0.52x	1.39x	CN¥-130.74 Million
2024	9.71%	13.27%	0.55x	1.34x	CN¥-23.14 Million
2025	9.60%	13.65%	0.55x	1.28x	CN¥-34.49 Million

Industry Comparison

This section compares Guobang Pharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $1,554,577,785
Average return on equity (ROE) among peers: 7.31%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guobang Pharma Ltd (605507)	CN¥8.40 Billion	16.46%	0.35x	$1.80 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.45 Billion	1.52%	1.57x	$485.12 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$576.00 Million	3.15%	0.28x	$363.11 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.12 Billion	13.25%	0.26x	$4.79 Billion
Livzon Pharmaceutical Group Inc (000513)	$623.47 Million	16.22%	0.40x	$2.70 Billion
Wedge Industrial Co Ltd (000534)	$654.70 Million	1.92%	0.87x	$1.28 Billion
Yunnan Baiyao Group Co Ltd (000538)	$184.00 Million	12.94%	0.09x	$14.40 Billion
Hainan Haiyao Co Ltd (000566)	$2.20 Billion	-4.84%	2.35x	$770.77 Million
Tus Pharmaceutical Group Co Ltd (000590)	$728.20 Million	3.47%	0.58x	$275.43 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.67 Billion	4.59%	1.27x	$925.00 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$2.34 Billion	20.86%	0.40x	$3.01 Billion

About Guobang Pharma Ltd

SHG:605507 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.80 Billion

CN¥12.29 Billion CNY

Market Cap Rank

#6303 Global

#1215 in China

Share Price

CN¥15.71

Change (1 day)

-0.63%

52-Week Range

CN¥14.50 - CN¥29.25

All Time High

CN¥43.71